Noradrenergic dysfunction in Alzheimer's disease

The brain noradrenergic system supplies the neurotransmitter norepinephrine throughout the brain via widespread efferent projections, and plays a pivotal role in modulating cognitive activities in the cortex. Profound noradrenergic degeneration in Alzheimer's disease (AD) patients has been observed for decades, with recent research suggesting that the locus coeruleus (where noradrenergic neurons are mainly located) is a predominant site where AD-related pathology begins. Mounting evidence indicates that the loss of noradrenergic innervation greatly exacerbates AD pathogenesis and progression, although the precise roles of noradrenergic components in AD pathogenesis remain unclear. The aim of this review is to summarize current findings on noradrenergic dysfunction in AD, as well as to point out deficiencies in our knowledge where more research is needed.

[1]  A. Mustaca,et al.  Corticosterone and propranolol's role on taste recognition memory , 2014, Pharmacology, Biochemistry and Behavior.

[2]  T. van Groen,et al.  α2A adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction , 2014, Proceedings of the National Academy of Sciences.

[3]  Abbas Ali Vafaei,et al.  Propranolol–induced Impairment of Contextual Fear Memory Reconsolidation in Rats: A similar Effect on Weak and Strong Recent and Remote Memories , 2014, Basic and Clinical Neuroscience.

[4]  G. Eichele,et al.  Ear2 Deletion Causes Early Memory and Learning Deficits in APP/PS1 Mice , 2014, The Journal of Neuroscience.

[5]  M. Zarrindast,et al.  Hippocampal α-adrenoceptors involve in the effect of histamine on spatial learning , 2014, Physiology and Behavior.

[6]  Yasuo Terayama,et al.  Detection of changes in the locus coeruleus in patients with mild cognitive impairment and Alzheimer's disease: High-resolution fast spin-echo T1-weighted imaging , 2014, Geriatrics & gerontology international.

[7]  Yong-Di Zhou,et al.  Distributed neural networks of tactile working memory , 2013, Journal of Physiology-Paris.

[8]  A. Bielawski,et al.  α_1-Adrenergic receptor subtypes in the central nervous system: insights from genetically engineered mouse models , 2013, Pharmacological reports : PR.

[9]  D. Diamond,et al.  Differential effectiveness of tianeptine, clonidine and amitriptyline in blocking traumatic memory expression, anxiety and hypertension in an animal model of PTSD , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[10]  M. Ramírez,et al.  Propranolol reduces cognitive deficits, amyloid β levels, tau phosphorylation and insulin resistance in response to chronic corticosterone administration. , 2013, The international journal of neuropsychopharmacology.

[11]  A. Carobrez,et al.  Systemic or intra-prelimbic cortex infusion of prazosin impairs fear memory reconsolidation , 2013, Behavioural Brain Research.

[12]  A. Carobrez,et al.  Enhanced noradrenergic activity potentiates fear memory consolidation and reconsolidation by differentially recruiting α1- and β-adrenergic receptors. , 2013, Learning & memory.

[13]  T. Robbins,et al.  Noradrenergic modulation of cognition: Therapeutic implications , 2013, Journal of psychopharmacology.

[14]  H. Pape,et al.  Selective Loss of Noradrenaline Exacerbates Early Cognitive Dysfunction and Synaptic Deficits in APP/PS1 Mice , 2013, Biological Psychiatry.

[15]  J. Hell,et al.  β2 Adrenergic Receptor, Protein Kinase A (PKA) and c-Jun N-terminal Kinase (JNK) Signaling Pathways Mediate Tau Pathology in Alzheimer Disease Models* , 2013, The Journal of Biological Chemistry.

[16]  M. Ramírez,et al.  Propranolol restores cognitive deficits and improves amyloid and Tau pathologies in a senescence-accelerated mouse model , 2013, Neuropharmacology.

[17]  R. Vassar,et al.  Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation , 2013, Molecular Neurodegeneration.

[18]  H. Braak,et al.  Where, when, and in what form does sporadic Alzheimer's disease begin? , 2012, Current opinion in neurology.

[19]  Qin Wang,et al.  α2 adrenergic receptor dysregulation in depressive disorders: Implications for the neurobiology of depression and antidepressant therapy , 2012, Neuroscience & Biobehavioral Reviews.

[20]  K. Nader,et al.  Preclinical Evaluation of Reconsolidation Blockade by Clonidine as a Potential Novel Treatment for Posttraumatic Stress Disorder , 2012, Neuropsychopharmacology.

[21]  S. Kalinin,et al.  The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease , 2012, Neurobiology of Aging.

[22]  M. Nedergaard,et al.  Norepinephrine: A Neuromodulator That Boosts the Function of Multiple Cell Types to Optimize CNS Performance , 2012, Neurochemical Research.

[23]  B Croisile,et al.  High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease , 2012, Molecular Psychiatry.

[24]  N. Hübner,et al.  Identification of Alzheimer disease risk genotype that predicts efficiency of SORL1 expression in the brain. , 2012, Archives of Neurology.

[25]  R. Drugan,et al.  Morris water maze performance deficit produced by intermittent swim stress is partially mediated by norepinephrine , 2012, Pharmacology, Biochemistry and Behavior.

[26]  V. Sheibani,et al.  Effect of DSP-4 induced central noradrenergic depletion on tactile learning in rat , 2012, Neurological Research.

[27]  P. Simpson,et al.  Long-Term α1A-Adrenergic Receptor Stimulation Improves Synaptic Plasticity, Cognitive Function, Mood, and Longevity , 2011, Molecular Pharmacology.

[28]  S. Thomas,et al.  Xamoterol impairs hippocampus-dependent emotional memory retrieval via Gi/o-coupled β2-adrenergic signaling. , 2011, Learning & memory (Cold Spring Harbor, N.Y.).

[29]  Yunjia Chen,et al.  The Antidepressant Desipramine Is an Arrestin-biased Ligand at the α2A-Adrenergic Receptor Driving Receptor Down-regulation in Vitro and in Vivo* , 2011, The Journal of Biological Chemistry.

[30]  Y. Xiang.  Compartmentalization of &bgr;-Adrenergic Signals in Cardiomyocytes , 2011, Circulation Research.

[31]  M. Heneka,et al.  Distinct adrenergic system changes and neuroinflammation in response to induced locus ceruleus degeneration in APP/PS1 transgenic mice , 2011, Neuroscience.

[32]  G. Scullion,et al.  Chronic treatment with the α2-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APP×PS1 transgenic mice without altering β-amyloid plaque load or astrocytosis , 2011, Neuropharmacology.

[33]  P. Deloukas,et al.  The dopamine β-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project , 2010, BMC Medical Genetics.

[34]  M. Heneka,et al.  Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits , 2010, Neurochemistry International.

[35]  A. Arnsten,et al.  Methylphenidate and atomoxetine enhance prefrontal function through α2-adrenergic and dopamine D1 receptors. , 2010, Journal of the American Academy of Child and Adolescent Psychiatry.

[36]  B. Gulyás,et al.  The norepinephrine transporter (NET) radioligand (S,S)-[18F]FMeNER-D2 shows significant decreases in NET density in the human brain in Alzheimer's disease: A post-mortem autoradiographic study , 2010, Neurochemistry International.

[37]  F. Kirchhoff,et al.  Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine , 2010, Proceedings of the National Academy of Sciences.

[38]  H. Yamaguchi,et al.  Gender effect on the accumulation of hyperphosphorylated tau in the brain of locus-ceruleus-injured APP-transgenic mouse , 2010, Neuroscience Letters.

[39]  P. Aisen,et al.  Restoration of Norepinephrine-Modulated Contextual Memory in a Mouse Model of Down Syndrome , 2009, Science Translational Medicine.

[40]  F. Schmitt,et al.  Expression of SORL1 and a novel SORL1 splice variant in normal and Alzheimers disease brain , 2009, Molecular Neurodegeneration.

[41]  R. Anwyl,et al.  Inhibition of LTP by beta-amyloid is prevented by activation of β2 adrenoceptors and stimulation of the cAMP/PKA signalling pathway , 2009, Neurobiology of Aging.

[42]  Jane B Shofer,et al.  Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. , 2009, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[43]  J. Kulisevsky,et al.  Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances , 2009, Journal of neural transmission.

[44]  F. Jourdan,et al.  Early locus coeruleus degeneration and olfactory dysfunctions in Tg2576 mice , 2009, Neurobiology of Aging.

[45]  D. Borchelt,et al.  Amyloid Pathology Is Associated with Progressive Monoaminergic Neurodegeneration in a Transgenic Mouse Model of Alzheimer's Disease , 2008, The Journal of Neuroscience.

[46]  Robert C. Green,et al.  Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. , 2008, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[47]  Bao-Ming Li,et al.  β1‐ and β2‐Adrenoceptors in basolateral nucleus of amygdala and their roles in consolidation of fear memory in rats , 2008, Hippocampus.

[48]  L. Tan,et al.  Polymorphisms at the β2-adrenergic receptor gene influence Alzheimer's disease susceptibility , 2008, Brain Research.

[49]  L. Kenton,et al.  Combined but not Individual Administration of β-Adrenergic and Serotonergic Antagonists Impairs Water Maze Acquisition in the Rat , 2008, Neuropsychopharmacology.

[50]  N. Lemon,et al.  Beta-adrenergic receptor activation during distinct patterns of stimulation critically modulates the PKA-dependence of LTP in the mouse hippocampus. , 2008, Learning & memory (Cold Spring Harbor, N.Y.).

[51]  N. Burgess,et al.  The hippocampus and memory: insights from spatial processing , 2008, Nature Reviews Neuroscience.

[52]  F. Jourdan,et al.  Noradrenergic control of odor recognition in a nonassociative olfactory learning task in the mouse. , 2007, Learning & memory.

[53]  L. Hein,et al.  α2-Adrenoceptor subtypes—Unexpected functions for receptors and ligands derived from gene-targeted mouse models , 2007, Neurochemistry International.

[54]  S. Kalinin,et al.  Noradrenaline deficiency in brain increases β-amyloid plaque burden in an animal model of Alzheimer's disease , 2007, Neurobiology of Aging.

[55]  E. Peskind,et al.  Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: Evidence of compensatory changes , 2007, Neuroscience.

[56]  D. McCormick,et al.  α2A-Adrenoceptors Strengthen Working Memory Networks by Inhibiting cAMP-HCN Channel Signaling in Prefrontal Cortex , 2007, Cell.

[57]  D. Perez.  Structure–function of α1-adrenergic receptors , 2007 .

[58]  M. Mesulam,et al.  Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease , 2007, Neurobiology of Aging.

[59]  J. Richardson,et al.  Repeated administration of the noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) modulates neuroinflammation and amyloid plaque load in mice bearing amyloid precursor protein and presenilin-1 mutant transgenes , 2007, Journal of Neuroinflammation.

[60]  K. Lunetta,et al.  The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease , 2007, Nature Genetics.

[61]  L. Hein.  Adrenoceptors and signal transduction in neurons , 2006, Cell and Tissue Research.

[62]  P. Zandi,et al.  Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. , 2006, Archives of neurology.

[63]  K. Perry,et al.  Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine , 2006, Molecular Psychiatry.

[64]  E. Peskind,et al.  Compensatory Changes in the Noradrenergic Nervous System in the Locus Ceruleus and Hippocampus of Postmortem Subjects with Alzheimer's Disease and Dementia with Lewy Bodies , 2006, The Journal of Neuroscience.

[65]  Ming Ouyang,et al.  A requirement for memory retrieval during and after long-term extinction learning. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Brooke N. Bourdélat-Parks,et al.  Genetic reduction of noradrenergic function alters social memory and reduces aggression in mice , 2005, Behavioural Brain Research.

[67]  D. Schubert.  Glucose metabolism and Alzheimer's disease , 2005, Ageing Research Reviews.

[68]  D. Tsuang,et al.  Propranolol for Disruptive Behaviors in Nursing Home Residents With Probable or Possible Alzheimer Disease: A Placebo-Controlled Study , 2005, Alzheimer disease and associated disorders.

[69]  F. Giubilei,et al.  Increased lymphocyte dopamine beta-hydroxylase immunoreactivity in Alzheimer's disease: compensatory response to cholinergic deficit? , 2004, Dementia and Geriatric Cognitive Disorders.

[70]  A. Levey,et al.  Loss of apolipoprotein E receptor LR11 in Alzheimer disease. , 2004, Archives of neurology.

[71]  Antonio S. Tutor,et al.  Polymorphism in genes involved in adrenergic signaling associated with Alzheimer’s , 2004, Neurobiology of Aging.

[72]  R. Hall.  β-Adrenergic receptors and their interacting proteins , 2004 .

[73]  A. Rosenquist,et al.  Noradrenergic mechanisms in neurodegenerative diseases: a theory , 2004, Brain Research Reviews.

[74]  Chris Zarow,et al.  Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. , 2003, Archives of neurology.

[75]  Kenji F. Tanaka,et al.  Existence of functional β1‐ and β2‐adrenergic receptors on microglia , 2002, Journal of neuroscience research.

[76]  Brian K. Kobilka,et al.  Mutation of the α2A-Adrenoceptor Impairs Working Memory Performance and Annuls Cognitive Enhancement by Guanfacine , 2002, The Journal of Neuroscience.

[77]  F. Colpaert,et al.  Effects of acute and subchronic administration of dexefaroxan, an alpha(2)-adrenoceptor antagonist, on memory performance in young adult and aged rodents. , 2002, Journal of Pharmacology and Experimental Therapeutics.

[78]  M. Esiri,et al.  Noradrenergic changes, aggressive behavior, and cognition in patients with dementia , 2002, Biological Psychiatry.

[79]  E. Peskind,et al.  Increased alpha 2-adrenergic receptor binding in locus coeruleus projection areas in dementia with Lewy bodies , 2001, Neurobiology of Aging.

[80]  C. Marsden,et al.  Effects of central noradrenaline depletion by the selective neurotoxin DSP-4 on the behaviour of the isolated rat in the elevated plus maze and water maze , 2001, Psychopharmacology.

[81]  J. Sirviö,et al.  The effects of a specific alpha(2)-adrenoceptor antagonist, atipamezole, on cognitive performance and brain neurochemistry in aged Fisher 344 rats. , 2000, European journal of pharmacology.

[82]  D. Goldstein,et al.  Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer’s disease , 1999, Biological Psychiatry.

[83]  W. Kamphorst,et al.  Increased activity of surviving locus ceruleus neurons in Alzheimer's disease , 1999, Annals of neurology.

[84]  J. Sirviö,et al.  Stimulation of alpha-1 adrenergic receptors facilitates spatial learning in rats , 1998, European Neuropsychopharmacology.

[85]  M. Ohno,et al.  Noradrenergic DSP-4 Lesions Aggravate Impairment of Working Memory Produced by Hippocampal Muscarinic Blockade in Rats , 1997, Pharmacology Biochemistry and Behavior.

[86]  J. Sirviö,et al.  Effects of St-587 and prazosin on water maze and passive avoidance performance of scopolamine-treated rats , 1996, Pharmacology Biochemistry and Behavior.

[87]  J. Winslow,et al.  α2-Adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat , 1996, Psychopharmacology.

[88]  E. Peskind,et al.  Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. , 1995, Archives of general psychiatry.

[89]  C. Cotman,et al.  Low‐Dose Propranolol Reduces Aggression and Agitation Resembling That Associated with Orbitofrontal Dysfunction in Elderly Demented Patients , 1995, Alzheimer disease and associated disorders.

[90]  S. Tejani-butt,et al.  Norepinephrine transporter sites are decreased in the locus coeruleus in Alzheimer's disease , 1993, Brain Research.

[91]  J. García-Sevilla,et al.  Non-adrenoceptor [3H]idazoxan binding sites (I2-imidazoline sites) are increased in postmortem brain from patients with Alzheimer's disease , 1993, Neuroscience Letters.

[92]  J. Cai,et al.  Reserpine impairs spatial working memory performance in monkeys: reversal by the α2-adrenergic agonist clonidine , 1993, Brain Research.

[93]  J. Blank,et al.  Role of olfactory bulb norepinephrine in the identification and recognition of chemical cues , 1993, Physiology & Behavior.

[94]  J. Bohl,et al.  Beta-adrenoceptor density and subtype distribution in cerebellum and hippocampus from patients with Alzheimer's disease , 1993, Naunyn-Schmiedeberg's Archives of Pharmacology.

[95]  G. Reynolds,et al.  Monoamine neurotransmitters and their metabolites in brain regions in alzheimer's disease: A postmortem study , 1992, Cellular and Molecular Neurobiology.

[96]  J. Sutin,et al.  Resting and reactive astrocytes express adrenergic receptors in the adult rat brain , 1992, Brain Research Bulletin.

[97]  Á. Pazos,et al.  Loss of high-affinity α 2-adrenoceptors in Alzheimer's disease: An autoradiographic study in frontal cortex and hippocampus , 1992, Neuroscience Letters.

[98]  L. Teri,et al.  Imipramine in the treatment of depressed Alzheimer's patients: impact on cognition. , 1991, Journal of gerontology.

[99]  J. Sirviö,et al.  The effects of noradrenergic neurotoxin, DSP-4, on the performance of young and aged rats in spatial navigation task , 1991, Brain Research.

[100]  R. Kalaria,et al.  Adrenergic receptors in aging and Alzheimer's disease: Decreased α2-receptors demonstrated by [3 H]p-aminoclonidine binding in prefrontal cortex , 1991, Neurobiology of Aging.

[101]  F. Sallee,et al.  Clinical Pharmacokinetics of Imipramine and Desipramine , 1990, Clinical pharmacokinetics.

[102]  J. D. McGaugh,et al.  Concurrent muscarinic and β-adrenergic blockade in rats impairs place-learning in a water maze and retention of inhibitory avoidance , 1990, Brain Research.

[103]  M. Tabaton,et al.  Adrenergic Receptors in Aging and Alzheimer's Disease: Increased β2‐Receptors in Prefrontal Cortex and Hippocampus , 1989, Journal of neurochemistry.

[104]  R. Kalaria.  Characterization of [125I]HEAT binding to α1-receptors in human brain: assessment in aging and Alzheimer's disease , 1989, Brain Research.

[105]  Y. Michotte,et al.  Monoaminergic neurotransmitters in Alzheimer's disease An HPLC study comparing presenile familial and sporadic senile cases , 1989, Journal of the Neurological Sciences.

[106]  A. Adunsky,et al.  Alzheimer's Dementia and Binding to Alpha2 Adrenoreceptors in Platelets , 1989, Journal of the American Geriatrics Society.

[107]  R. Kalaria,et al.  Brain microvessels are innervated by locus ceruleus noradrenergic neurons , 1989, Neuroscience Letters.

[108]  P. Goldman-Rakic,et al.  The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[109]  D. Sparks,et al.  Alzheimer's disease. Aminergic-cholinergic alterations in hypothalamus. , 1988, Archives of neurology.

[110]  M. Laakso,et al.  A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease , 1988, Journal of the Neurological Sciences.

[111]  D. Neary,et al.  Catecholaminergic neurones assessed ante-mortem in Alzheimer's disease , 1987, Brain Research.

[112]  P. Goldman-Rakic,et al.  Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. , 1985, Science.

[113]  Shigenobu Nakamura,et al.  Dopamine-β-hydroxylase activities in serum and cerebrospinal fluid of aged and demented patients , 1984, Journal of the Neurological Sciences.

[114]  F. E. Bloom,et al.  Loss of pigmented dopamine-β-hydroxylase positive cells from locus coeruleus in senile dementia of alzheimer's type , 1983, Neuroscience Letters.

[115]  P. Yates,et al.  Changes in the Monoamine Containing Neurones of the Human Cns in Senile Dementia , 1980, British Journal of Psychiatry.

[116]  B. K. Hartman,et al.  The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine‐B‐hydroxylase as a marker , 1975, The Journal of comparative neurology.

[117]  Springer-Verlag Wien.  Polymorphisms in the aldehyde dehydrogenase 2 and dopamine b hydroxylase genes are not associated with Alzheimer's disease , 2014 .

[118]  G. Pasinetti,et al.  Investigation of nebivolol as a novel therapeutic agent for the treatment of Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[119]  A. Stuchlik,et al.  Effect of block of α-1-adrenoceptors on overall motor activity but not on spatial cognition in the object-position recognition task. , 2013, Physiological research.

[120]  G. Aston-Jones,et al.  A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model. , 2011, Journal of Alzheimer's disease : JAD.

[121]  K. Hensley.  Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. , 2010, Journal of Alzheimer's disease : JAD.

[122]  E. Seu,et al.  Effects of atomoxetine and methylphenidate on performance of a lateralized reaction time task in rats , 2008, Psychopharmacology.

[123]  D. Perez.  Structure-function of alpha1-adrenergic receptors. , 2007, Biochemical pharmacology.

[124]  K. Lange,et al.  Effects of the noradrenergic neurotoxin DSP4 on spatial memory in the rat , 2007, Journal of neural transmission.

[125]  Mathias Hoehn,et al.  Locus Ceruleus Degeneration Promotes Alzheimer Pathogenesis in Amyloid Precursor Protein 23 Transgenic Mice , 2006, The Journal of Neuroscience.

[126]  Yun Bai,et al.  Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. , 2006, Nature medicine.

[127]  W. Summers.  The management of agitation in demented patients with propranolol. , 2006, Journal of Alzheimer's Disease.

[128]  K. Minneman,et al.  Recent progress in alpha1-adrenergic receptor research. , 2005, Acta pharmacologica Sinica.

[129]  J. Mcgaugh,et al.  Involvement of the amygdala in the memory-enhancing effects of clenbuterol , 2005, Psychopharmacology.

[130]  J. Mcgaugh,et al.  Impairment of active avoidance by the noradrenergic neurotoxin, DSP4: attenuation by post-training epinephrine , 2005, Psychopharmacology.

[131]  M. Philipp,et al.  Adrenergic receptor knockout mice: distinct functions of 9 receptor subtypes. , 2004, Pharmacology & therapeutics.

[132]  G. Tsujimoto,et al.  Characteristics of behavioral abnormalities in alpha1d-adrenoceptors deficient mice. , 2004, Behavioural brain research.

[133]  R. Hall.  Beta-adrenergic receptors and their interacting proteins. , 2004, Seminars in Cell and Developmental Biology.

[134]  D. Cain,et al.  Combined beta-adrenergic and cholinergic antagonism produces behavioral and cognitive impairments in the water maze: implications for Alzheimer disease and pharmacotherapy with beta-adrenergic antagonists. , 2003, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[135]  O. Valladares,et al.  α1d Adrenoceptor signaling is required for stimulus induced locomotor activity , 2003, Molecular Psychiatry.

[136]  Mark A. Smith,et al.  Alzheimer Disease and Oxidative Stress , 2002, Journal of Biomedicine and Biotechnology.

[137]  E. Peskind,et al.  Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration. , 1997, The American journal of psychiatry.

[138]  R. Levy,et al.  Disproportionate loss of noradrenergic and cholinergic neurons as cause of depression in Alzheimer's disease--a hypothesis. , 1994, Pharmacopsychiatry.

[139]  H. Tohgi,et al.  Concentration of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vascular dementia of the Binswanger type , 1992, Journal of neural transmission. Parkinson's disease and dementia section.

[140]  J. Sutin,et al.  Expression of adrenergic receptors in individual astrocytes and motor neurons isolated from the adult rat brain , 1992, Glia.

[141]  F. Petraglia,et al.  Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type , 1992, Journal of Neural Transmission - Parkinsons Disease and Dementia Section.

[142]  M. E. Pauszek.  Propranolol for treatment of agitation in senile dementia. , 1991, Indiana medicine : the journal of the Indiana State Medical Association.

[143]  K. McCarthy,et al.  Expression of beta‐adrenergic receptors by astrocytes isolated from adult rat cortex , 1989, Glia.

[144]  M. Roth,et al.  NEURONAL DEGENERATION IN LOCUS CERULEUS AND CORTICAL CORRELATES OF ALZHEIMER DISEASE , 1987, Alzheimer disease and associated disorders.

[145]  P. Goldman-Rakic,et al.  Noradrenergic mechanisms in age-related cognitive decline. , 1987, Journal of neural transmission. Supplementum.

[146]  T. Taniguchi,et al.  Biochemical characterization of alpha-adrenergic receptors in human brain and changes in Alzheimer-type dementia. , 1986, Journal of neurochemistry.